Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs JD.Com Inc (JD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs JD.Com Inc — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B), while JD.Com Inc trades at $27.09 (market cap $36.62B). The key difference: JD.Com Inc is far larger — about 6.1× Iovance Biotherapeutics Inc. Common Stock's market cap, and JD.Com Inc pays a 3.72% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and JD.Com Inc for 85 Days on average.
| IOVA | JD | |
|---|---|---|
Market Cap | $6.04B | $36.62B |
Volume | 14,805,993 | 6,571,477 |
Sector | Health | Consumer Cyclical |
52-Week High | $14.82 | $34.53 |
52-Week Low | $1.81 | $25.19 |
Typical Hold Time | 0 Days | 85 Days |
Enterprise Value | $5.97B | $19.26B |
Dividend Yield | — | 3.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JD.com (JD) trades at $26.91, down 0.44% on the day, amid mixed technical signals but strong fundamental value. The stock shows a bullish overall technical signal despite bearish moving averages, with key support at $26. Valuation metrics are attractive with a P/E of 17.9 and P/S of 0.2, while recent earnings beats and a pending Q3 report highlight operational strength. Positive news includes potential EU approval for the $2.5 billion Ceconomy acquisition (Reuters, 2026-10-02).
The outlook remains favorable given deep undervaluation, robust cash flow, and analyst consensus pointing to 33% upside to the $35.86 price target. Risks include revenue growth deceleration, regulatory scrutiny from EU probes, and macroeconomic pressures on Chinese equities. The stock's net cash position and institutional accumulation support a constructive view for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →
